Effectiveness and Impact of the 4CMenB Vaccine against Group B Meningococcal Disease in Two Italian Regions Using Different Vaccination Schedules: A Five-Year Retrospective Observational Study (2014–2018)

Background: A few years after the introduction in Italy of a four-component anti-meningococcal B vaccine (4CMenB), we evaluated the effectiveness and impact of vaccination in two regions using different schedules (2, 4, 6, 12 months in Tuscany vs. 7, 9, 15 months in Veneto) through an observational...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Vaccines (Basel)
Autors principals: Azzari, Chiara, Moriondo, Maria, Nieddu, Francesco, Guarnieri, Valentina, Lodi, Lorenzo, Canessa, Clementina, Indolfi, Giuseppe, Giovannini, Mattia, Napoletano, Giuseppina, Russo, Francesca, Baldovin, Tatjana, Cocchio, Silvia, Ricci, Silvia, Baldo, Vincenzo
Format: Artigo
Idioma:Inglês
Publicat: MDPI 2020
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7563708/
https://ncbi.nlm.nih.gov/pubmed/32842669
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/vaccines8030469
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars